Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

trong or moderate inhibitors of CYP3A. If a moderate CYP3A inhibitor must be used, reduce the IMBRUVICA dose.

CYP3A Inducers - Avoid co-administration with strong CYP3A inducers.

SPECIAL POPULATIONS - Hepatic Impairment - Avoid use in patients with baseline hepatic impairment.

Because everyone is different, it is not possible to predict what side effects any one patient will have. Patients with questions or concerns about side effects should talk to their doctor.

Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch.

For more information please read the IMBRUVICA Full Prescribing Information at www.IMBRUVICA.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions ar
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that certain members of the executive ... Conference to be held September 8-10, 2014 in ... Chief Executive Officer and President, is scheduled to present ... at 10:55 a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
(Date:8/27/2014)... shapes many aspects of our lives. But in addition ... set during development, but can be altered by our ... our parents and grandparents. , The epigenome consists of ... determine whether genes are expressed or silenced. , This ... but also that it may be possible to diagnose ...
(Date:8/27/2014)... August 27, 2014 Tejal K. Gandhi, MD, ... (NPSF) and the NPSF Lucian Leape Institute, is among ... August 25 issue of Modern Healthcare magazine. Also on the ... Andrew Sussman, MD, MBA; NPSF Lucian Leape Institute members ... who is a member of both the Institute and the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps Research ... specific signaling pathway can be associated with alcohol dependence. ... gene, called neurofibromatosis type 1 (Nf1), which TSRI scientists ... new research shows Nf1 regulates gamma-aminobutyric acid (GABA), a ... , "This novel and seminal study provides insights ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... West Orange, NJ. August 27, 2014. Kessler Foundation ... cultural competence in brain injury research and rehabilitation. ... Krch, PhD: Issues of cultural diversity in acquired ... by Neurorehabilitation . Drs. Lequerica and ... (TBI) Research at Kessler Foundation and co-investigators for ...
Breaking Medicine News(10 mins):Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... disease has joined poaching and habitat loss as a ... as they have become restricted to ever-smaller populations. Despite ... closest living relatives from ecological extinction are largely failing, ... threats and find innovative solutions. In response to ...
... CHAPEL HILL, N.C. UNC researchers have discovered how ... heart diseases keeps the critical organ from developing properly. According ... distort the shape of cardiac muscle cells so they are ... study also shows that treatment with a drug that regulates ...
... -- (Feb. 6, 2012) -- Researchers at Rice University and ... into cells that form blood vessels. Their success offers hope ... patches to repair infant hearts. "We want to come ... tissue made from stem cells sloughed off by the infant ...
... A new study analyses the influence that certain birth and ... of breast cancer risk. The results reveal that women born ... taller and thinner than the average girl prior to puberty ... increased risk of developing breast cancer. Although the ...
... , SUNDAY, Feb. 5 (HealthDay News) -- More than 60 ... a social networking site, and many spend more than two ... American Academy of Child and Adolescent Psychiatry. Like many ... teens, and parents need to help their children use these ...
... children in the United States were hospitalized due to child ... School of Medicine researchers report in a new study. ... Pediatrics (published online Feb. 6). Several measures ... abuse, including data from Child Protective Services. But until now ...
Cached Medicine News:Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 2Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 3Health News:'ROCK' off: Study establishes molecular link between genetic defect and heart malformation 2Health News:Scientists make strides toward fixing infant hearts 2Health News:Scientists make strides toward fixing infant hearts 3Health News:Women born to older mothers have a higher risk of developing breast cancer 2Health News:Safe Social Networking Tips for Teens 2Health News:Children hospitalized at alarming rate due to abuse 2
... ultra versatile model angulates for vascular ... the height of the support leg, ... post, or double tee foot. Add ... comfort and stability. A convenient bracket ...
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... OL1000 Bone Growth Stimulators are portable, battery-powered ... noninvasive treatment of an established nonunion fracture ... and flat bones. , ... of healing of 60.7% in patients with ...
... The EBI OsteoGen surgically implanted bone growth ... of nonunions when surgery is already planned or ... the OsteoGen is totally surgically implanted, patients are ... site 24 hours a day for up to ...
Medicine Products: